Inventiva S.A. - American Depos (IVA) Stock Analysis

Q: What is the IVA stock price target?

Take-profit $13.16 (+159.1% upside). Target $13.16 (+159.1%), stop $4.72 (−7.6%), A.R:R 16.5:1.

Q: Is IVA overvalued or undervalued?

Inventiva S.A. - American Depos trades at a P/E of N/A (forward -5.4). TrendMatrix value score: 9.0/10. Overall verdict: Hold.

Q: What do analysts say about IVA?

16 analysts cover IVA with a consensus score of 4.4/5. Average price target: $15.

HoldVALUE-TRAP 3/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

$5.08+159.1% A.UpsideScore 5.6/10#35 of 158 Biotechnology

Stop $4.72Target $13.16(analyst − 13%)A.R:R 16.5:1

Analyst target$15.13+197.8%13 analysts

$13.16our TP

$5.08price

$15.13mean

$26

Hold if already holding. Not a fresh buy at $5.08, but acceptable to hold if already in. Reasons: Negative momentum; Value-trap signals (3/5): Revenue declining (-89.9% YoY), Margin compression (op margin -6710.7%), Negative free cash flow. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 148d clear, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Thesis

Rewards

Strong earnings beat streak (3/4)

Attractive valuation

Analyst upside: 159%

Risks

Negative momentum

Value-trap signals (3/5): Revenue declining (-89.9% YoY), Margin compression (op margin -6710.7%), Negative free cash flow

Key Metrics

P/E (TTM)—

P/E (Fwd)-5.4

Mkt Cap$1.0B

EV/EBITDA-8.7

Profit Mgn0.0%

ROE—

Rev Growth-89.9%

Beta0.95

DividendNone

Rating analysts16

Quality Signals

Piotroski F4/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality4.015%0.60

Growth5.015%0.75

Momentum2.210%0.22

Sentiment6.710%0.67

Insider Activity6.110%0.61

Peer Rank3.910%0.39

Technical Setup6.05%0.30

Risk Profile6.95%0.35

Catalyst7.55%0.38

Overall (Σ contributions)5.61

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Obv

1.0

Ma Position

2.2

Macd

3.5

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+6.8%/30d) — pullback in uptrend, not confirmed weakness

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.7

Value Rank

5.0

Quality Rank

5.0

GatesMomentum 2.2<4.5A.R:R 16.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 148d clearSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

46 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $4.87Resistance $5.80

Price Targets

$13

A.Upside+159.1%

A.R:R16.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Momentum score 2.2/10 — below 4.5 minimum

Earnings

3/4 beats

Next Earnings2026-09-25 (148d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is IVA stock a buy right now?

Hold if already holding. Not a fresh buy at $5.08, but acceptable to hold if already in. Reasons: Negative momentum; Value-trap signals (3/5): Revenue declining (-89.9% YoY), Margin compression (op margin -6710.7%), Negative free cash flow. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Mixed signals. Hold existing position. Target $13.16 (+159.1%), stop $4.72 (−7.6%), A.R:R 16.5:1. Score 5.6/10, moderate confidence.

What is the IVA stock price target?

Take-profit target: $13.16 (+159.1% upside). Target $13.16 (+159.1%), stop $4.72 (−7.6%), A.R:R 16.5:1. Stop-loss: $4.72.

What are the risks of investing in IVA?

Negative momentum; Value-trap signals (3/5): Revenue declining (-89.9% YoY), Margin compression (op margin -6710.7%), Negative free cash flow.

Is IVA overvalued or undervalued?

Inventiva S.A. - American Depos trades at a P/E of N/A (forward -5.4). TrendMatrix value score: 9.0/10. Verdict: Hold.

What do analysts say about IVA?

16 analysts cover IVA with a consensus score of 4.4/5. Average price target: $15.

What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.